AVEO Pharmaceuticals — Investor Presentation (November 2019)
36 slides from AVEO Pharmaceuticals's investor presentation, Nov 5, 2019
Slide 1: AVEO Overview November 2019
AVEO Overview November 2019
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements
Slide 3: AVEO Oncology: Strategy for Value Creation
| AVEO Oncology: Strategy for Value Creation Deep Pipeline Addressing Significant Unmet Needs Multiple oncology and non-oncology pipeline opportunities FOTIVDA® (tivozanib) — 10 Combinations (RCC, HCC, other) Selective VEGFR TKI has potential to enable unique tolerability in combination ONCOLOGY [cu
Slide 4: Multiple Potential Opportunities for Value Creation
Multiple Potential Opportunities for Value Creation
Slide 5: Financial Highlights
Financial Highlights Cash on hand to fund planned operations into 3Q 2021* * $40.2M in cash, cash equivalents, and marketable securities as of 2Q 2019 + $25.0M upfront payment from Kyowa Kirin received in 3Q 2019 * Runway includes paydown of debt, randomized phase 2 studies for ficlatuzumab in SCCHN
Slide 6: FOTIVDA (tivozanib) TIVO-3 Pivotal Phase Study
FOTIVDA® (tivozanib) TIVO-3 Pivotal Phase 3 Study
Slide 7: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor
Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor
Slide 8: TIVO-3: Study Design
TIVO-3: Study Design First stratified 3rd line dataset of patients with prior PD-1 exposure TIVO3 Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma N=350 Fd * Recurrent/metastatic RCC Ss | tivoz
Slide 9: TIVO-3: Superior PFS and ORR
TIVO-3: Superior PFS and ORR*
Slide 10: Progression-Free Survival – Key Subgroups
Progression-Free Survival – Key Subgroups*
Slide 11: Durable Disease Control with Tivozanib (Patients with > year PFS)
Durable Disease Control with Tivozanib (Patients with > 1 year PFS)
Slide 12: Secondary Endpoint – Overall Survival
Secondary Endpoint – Overall Survival
Slide 13: Pre-NDA Regulatory Feedback and POA
Pre-NDA Regulatory Feedback and POA
Slide 14: As OS Data Matures HR Improves
As OS Data Matures HR Improves
Slide 15: Treatment-Related Adverse Events (≥20% frequency in either arm)
Treatment-Related Adverse Events* (≥20% frequency in either arm)
Slide 16: Safety and Tolerability Results TIVO3
Safety and Tolerability Results* TIVO3 Tivozanib (N=173)* | Sorafenib (N=170)* Mean Number of Cycles Initiated 11.9 6.7 AEs Leading to Dose Reductions (%) 24 P=0.005 38 AEs Leading to Dose Interruption (%) 48 P=0.007 63 Treatment Related SAEs (%) 12 11 Treatment Related Deaths (%) fo) 0 Deaths withi
Slide 17: TIVO-3 Conclusions
TIVO-3 Conclusions TIVO-3 * Tivozanib significantly improves PFS and ORR compared to sorafenib in patients with treatment-refractory advanced RCC Y Tivozanib was superior in patients previously treated with checkpoint inhibitors as well as two VEGFR-TKIs v Responses with tivozanib were more durable
Slide 18: PD-1 Combination Opportunities
PD-1 Combination Opportunities
Slide 19: Tivozanib Properties May Provide Advantages in Combination with IO Therapy
Tivozanib Properties May Provide Advantages in Combination with IO Therapy
Slide 20: Phase Data Presented at ESMO in September 2019
Phase 2 Data Presented at ESMO in September 2019
Slide 21: ESMO 2019: Encouraging Safety Results
ESMO 2019: Encouraging Safety Results
Slide 22: ESMO 2019: Encouraging Efficacy
ESMO 2019: Encouraging Efficacy
Slide 23: Combination of PD-1 + VEGF TKIs: Promising Responses, All Phase 3 Currently 1st Line
Combination of PD-1 + VEGF TKIs: Promising Responses, All Phase 3 Currently 1st Line
Slide 24: TiNivo – Strong Efficacy Seen in Both Treatment Naive and Previously Treated Patients
TiNivo – Strong Efficacy Seen in Both Treatment Naive and Previously Treated Patients
Slide 25: Immuno-Oncology Clinical Collaboration with AstraZeneca
Immuno-Oncology Clinical Collaboration with AstraZeneca
Slide 26: Tivozanib Commercial Opportunity
Tivozanib Commercial Opportunity
Slide 27: If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States
If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States
Slide 28: Potential Relevance of Tivozanib in Refractory RCC
Potential Relevance of Tivozanib in Refractory RCC
Slide 29: FOTIVDA Commercialization in EU and ROW
FOTIVDA® Commercialization in EU and ROW
Slide 30: Pipeline and Near-Term Milestones
Pipeline and Near-Term Milestones
Slide 31: Tivozanib
Tivozanib VEGER 1, 2 and 3 Tyrosine Kinase Inhibitor Launched in Europe by EUSA as FOTIVDA? in first line RCC in November 2017 TIVO-3 study on-going for potential U.S. registration for RCC Tivozanib + OPDIVO® Phase 1/2 in collaboration with BMS complete in RCC Tivozanib + IMFINZI® Phase 1/2 in colla
Slide 32: Ficlatuzumab
2 Ficlatuzumab biodesix ® HGF Inhibitory Antibody with Optimal Blockade of c-Met * AML: Phase 1/2 trial of ficlatuzumab and cytarabine in refractory AML patients (n=18) * Demonstrated 50% CR in patients refractory to initial therapy * Randomized Phase 2 in planning * SCCHN: Randomized Phase 2 trial
Slide 33: AV-203 (CAN017)
AVv-203 (CANO17) OCANbridge Anti-ERBB3 MAb with Broad Therapeutic Potential CANbridge to fund clinical development through Phase 2 POC study Potential additional $40.0M development and regulatory/$90.0M commercial milestone Tiered low double-digit royalties for ex-NA rights Planned indication: squam
Slide 34: AV-380: First-in-Class, Anti-GDF15 MAb for Cachexia
AV-380 First-in-Class, Anti-GDF15 MAb for Cachexia * Cachexia affects approximately 5 million patients in the U.S. alone; affects up to 80% of advanced cancer patients and is responsible for approximately 30% of all cancer deaths! * Pre-clinical development underway to enable planned IND submission
Slide 35: AVEO Key Near Term Potential Milestones
AVEO Key Near Term Potential Milestones
Slide 36: AVEO Overview November 2019
AVEO Overview November 2019
AVEO Pharmaceuticals — Investor Presentation (November 2019) on 6ix